z-logo
Premium
Long‐term tolerability of phosphodiesterase‐5 inhibitors in pulmonary hypertension of sickle cell disease
Author(s) -
CramerBour Cassondra,
Ruhl Amy Parker,
Nouraie Seyed Mehdi,
Emeh Robert O.,
Ruopp Nicole F.,
Thein Swee Lay,
Weir Nargues A.,
Klings Elizabeth S.
Publication year - 2021
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13612
Subject(s) - medicine , tolerability , pulmonary hypertension , acute chest syndrome , cgmp specific phosphodiesterase type 5 , tadalafil , sildenafil , disease , sickle cell anemia , gastroenterology , adverse effect , surgery
Objectives Sickle cell disease‐related pulmonary hypertension (SCD‐PH) is a complex disorder with multifactorial contributory mechanisms. Previous trials have evaluated the efficacy of pulmonary arterial hypertension (PAH) therapies in SCD‐PH with mixed results. We hypothesized that a subset of patients with right heart catheterization (RHC) confirmed disease may benefit from PAH therapy. Methods We performed a retrospective chart review of patients with SCD‐PH diagnosed by RHC who were treated with phosphodiesterase 5 inhibitor (PDE5‐I) therapy for ≥4 months between 2008 and 2019 at two institutions. Results Thirty‐six patients were included in the analysis. The median age (IQR) upon PDE5‐I initiation was 47.5 years (35‐51.5 years); 58% were female and twenty‐nine (81%) had HbSS disease. Of these, 53% of patients had a history of acute chest syndrome, 42% had a history of venous thromboembolism, and 38% had imaging consistent with chronic thromboembolic PH. Patients were treated for a median duration of 25 months (IQR 13‐60 months). Use of PDE5‐I was associated with a significant improvement in symptoms as assessed by NYHA Class ( P  = .002). Conclusions In SCD patients with PH defined by RHC, PDE5‐I therapy was tolerated long‐term and may improve physical activity.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here